Sanofi Symposium EULAR 2025: The Clock is Ticking – When to Break Free from Glucocorticoids in PMR

This content was funded by Sanofi

In this symposium, Anisha Bharadwaj Dua explored the prevalence and impact of comorbidities in patients with polymyalgia rheumatica (PMR), importance of screening for patients on glucocorticoids (GC) therapy in PMR, and effective strategies to manage these comorbidities. 

Next, John Stone discussed the long-term impact of GC use in PMR, emphasizing the shift from daily to cumulative dose, the fact that there is no safe GC dose, persistent risks post-GC use, how to manage lack of clinically usable tools to assess GC toxicity risk, and effective GC tapering and discontinuation strategies in PMR. 

Finally, Andrea Rubbert-Roth delved into approaches to treatment adjustments based on disease severity and activity, comorbidities, and predictors of outcomes, with a focus on achieving remission off-treatment, maximizing quality of life, and minimizing GC, along with early intervention with GC-sparing therapies and insights from EULAR 2025 (in development), German and French recommendations in PMR.

Time stamps for video:

• Walking a Tightrope: Polymyalgia Rheumatica Treatment Amidst Comorbidities – 03:39 (Anisha Bharadwaj Dua) 

• Breaking the Glucocorticoids Golden Dose Myth in Polymyalgia Rheumatica – 14:07 (John H. Stone) 

• Chasing Remission, Not Steroids: A Polymyalgia Rheumatica Paradigm Shift – 36:10 (Andrea Rubbert-Roth)

1. University of Munich, Germany 

2. Northwestern University, Evanston, USA 

3. Massachusetts General Hospital, Boston, USA

4. St. Gallen Cantonal Hospital, Switzerland 

MAT-DE-2503196-V1.0-08/2025